文献速递心脑血管急症重症综合管理与镇静镇痛

丘脑脑出血导致第三脑室梗阻可预测CLEAR III试验中接受阿替普酶治疗患者的不良功能结局

Third Ventricle Obstruction by Thalamic Intracerebral Hemorrhage Predicts Poor Functional Outcome Among Patients Treated with Alteplase in the CLEAR III Trial.
PubMed 文献 · Neurocrit Care · 2019-01-01
一句话结论在CLEAR III试验中,阿替普酶治疗患者第三脑室被丘脑血肿梗阻与180天不良功能结局独立相关(mRS 4-6 OR 3.20)。

该研究基于CLEAR III试验,纳入小量脑出血合并大量脑室内出血患者,评估丘脑血肿或脑室内出血铸型导致第三脑室梗阻对180天功能结局的预测价值。结果显示,在生理盐水组中,脑室内出血梗阻第三脑室显著预测更高mRS(OR 1.87)和死亡率(OR 2.73),而血肿梗阻无此关联;在阿替普酶组中,血肿梗阻第三脑室显著预测mRS 4-6(OR 3.20)和更高mRS(OR 2.33),而脑室内出血梗阻无此关联。作者认为,阿替普酶清除脑室系统后,丘脑血肿对脑脊液通路的梗阻可能对功能恢复变得重要。

要点

  • 在阿替普酶治疗患者中,丘脑血肿导致第三脑室梗阻预测180天mRS 4-6(OR 3.20,95%CI 1.30-7.88)。
  • 在阿替普酶治疗患者中,丘脑血肿导致第三脑室梗阻预测180天更高mRS(OR 2.33,95%CI 1.24-4.35)。
  • 在生理盐水组中,脑室内出血梗阻第三脑室预测180天更高mRS(OR 1.87,95%CI 1.01-3.47)和死亡率(OR 2.73,95%CI 1.27-5.87)。
  • 阿替普酶组中脑室内出血梗阻第三脑室未显著预测不良结局,生理盐水组中血肿梗阻第三脑室亦未显著预测。
  • 模型已调整丘脑出血部位、血肿体积、脑室内出血体积、年龄、脑积水、基线GCS及治疗期间低脑灌注压百分比。

适用人群与场景

  • CLEAR III试验纳入的小量脑出血合并大量脑室内出血患者。
  • 患者接受脑室内阿替普酶或生理盐水冲洗治疗。

诊断标准与关键阈值

  • 第三脑室梗阻定义为:一个或多个轴位CT层面上第三脑室受压,肉眼可见阻碍脑脊液流动。
  • 若第三脑室被脑室内出血铸型,则按此评分。
  • 不良功能结局定义为:180天改良Rankin量表(mRS)4-6分、更高的mRS评分以及180天死亡率。

研究设计与关键结果

  • 研究类型:CLEAR III试验的二次分析。
  • 在生理盐水组中,脑室内出血梗阻第三脑室显著预测180天更高mRS(OR 1.87,95%CI 1.01-3.47)和180天死亡率(OR 2.73,95%CI 1.27-5.87),而血肿梗阻无显著预测作用。
  • 在阿替普酶组中,血肿梗阻第三脑室显著预测180天mRS 4-6(OR 3.20,95%CI 1.30-7.88)和更高mRS(OR 2.33,95%CI 1.24-4.35),而脑室内出血梗阻无显著预测作用。
  • 模型调整了丘脑出血部位、血肿体积、脑室内出血体积、年龄、脑积水、基线GCS以及治疗期间低脑灌注压百分比。

证据类型、等级与局限

  • 证据类型:基于CLEAR III随机对照试验的二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,一旦阿替普酶清除脑室系统,丘脑血肿导致的脑脊液通路梗阻可能对功能恢复变得重要。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: The Clot Lysis: Evaluating Accelerated Resolution of IVH trial examined whether irrigating the ventricular system with alteplase improved functional outcomes in patients with small intracerebral hemorrhage (ICH) and large intraventricular hemorrhage (IVH). Thalamic ICH location was common and was associated with poor outcome. One possible explanation is thalamic ICH-associated mass effect obstructing the third ventricle. We hypothesized that patients with thalamic ICH obstructing the third ventricle would have worse functional outcomes compared to patients without obstructing lesions.

METHODS: ICH obstruction of third ventricle was defined as third ventricle compression on 1 or more axial computed tomography slices visually impeding cerebral spinal fluid flow. If the third ventricle was casted with IVH, it was scored as such. Multivariable logistic regression analyses were used to determine whether obstruction of the third ventricle predicts poor functional outcomes defined as modified Rankin score (mRS) 4-6, higher mRS, and mortality at 180 days. Models were adjusted for thalamic ICH location, ICH volume, IVH volume, age, hydrocephalus, baseline Glasgow coma scale, and percentage of low cerebral perfusion pressures during treatment.

RESULTS: Among saline-treated patients, obstruction of the third ventricle by IVH was a significant predictor of higher mRS at 180 days (OR 1.87, CI 1.01-3.47) and mortality at 180 days (OR 2.73, CI 1.27-5.87) while obstruction by ICH was not. In contrast, among alteplase-treated patients, obstruction by ICH was a significant predictor of mRS 4-6 (OR 3.20, CI 1.30-7.88) and higher mRS at 180 days (OR 2.33, CI 1.24-4.35), while obstruction by IVH was not.

CONCLUSIONS: Poor outcomes were associated with mass-related obstruction of the third ventricle from thalamic ICH in alteplase-treated patients and from IVH in saline-treated patients. Once the ventricular system is cleared with alteplase, obstruction of cerebral spinal fluid flow from thalamic ICH might become important in functional recovery.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Ullman NL, Tahsili-Fahadan P, Thompson CB, et al. Third Ventricle Obstruction by Thalamic Intracerebral Hemorrhage Predicts Poor Functional Outcome Among Patients Treated with Alteplase in the CLEAR III Trial. Neurocrit Care. 2019. PMID: 30251074. doi:10.1007/s12028-018-0610-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。